Ocular Expression of Cyclin-dependent Kinase 5 in Patients with Proliferative Diabetic Retinopathy

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2021 Oct 25

PMID 34693664

Citations 1

Authors

Hiroki Sano

Kazuhiko Namekata

Masanori Niki

Kentaro Semba

Fumiko Murao

Takayuki Harada

Yoshinori Mitamura

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: Inhibition of peroxisome proliferator-activated receptor gamma (PPARγ) phosphorylation mediated by cyclin-dependent kinase 5 (Cdk5) is one of the main mechanisms of action of antidiabetic drugs. In this study, we analyzed the ocular expression and activation of Cdk5 in patients with proliferative diabetic retinopathy (PDR).

Materials And Methods: The concentrations of PPARγ, Cdk5 and its activating subunit (p35) were determined in the vitreous body of 24 PDR and 63 control eyes by enzyme-linked immunosorbent assay. In addition, the messenger ribonucleic acid and protein expression levels of PPARγ, Cdk5 and p35 were measured in proliferative neovascular membranes from seven PDR eyes and non-neovascular epiretinal membranes from five control eyes by quantitative real-time polymerase chain reaction and immunohistochemical analysis.

Results: PPARγ, Cdk5 and p35 concentrations in the vitreous body were significantly higher in the PDR group compared with the control group. There was also a positive significant correlation of Cdk5 with PPARγ and p35 in the PDR group. Furthermore, the messenger ribonucleic acid expression levels of PPARγ, Cdk5 and p35 in proliferative neovascular membranes were significantly higher in the PDR group compared with the control group. Immunostaining showed increased protein expression levels of PPARγ, Cdk5 and p35 in proliferative neovascular membranes in the PDR group compared with the control group.

Conclusions: Cdk5 activation is involved in PDR pathogenesis through PPARγ expression, and inhibition of Cdk5-mediated PPARγ phosphorylation might be a new therapeutic target for treatment of PDR.

Citing Articles

Ocular expression of cyclin-dependent kinase 5 in patients with proliferative diabetic retinopathy.

Sano H, Namekata K, Niki M, Semba K, Murao F, Harada T J Diabetes Investig. 2021; 13(4):628-637.

PMID: 34693664 PMC: 9017639. DOI: 10.1111/jdi.13702.

References

Aoun P, Simpkins J, Agarwal N . Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci. 2003; 44(7):2999-3004. DOI: 10.1167/iovs.02-1060. View

Lehrke M, Lazar M . The many faces of PPARgamma. Cell. 2005; 123(6):993-9. DOI: 10.1016/j.cell.2005.11.026. View

Xie W, Wang H, He Y, Li D, Gong L, Zhang Y . CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression. Int J Biol Sci. 2014; 10(2):192-9. PMC: 3927131. DOI: 10.7150/ijbs.7770. View

Burgos R, Mateo C, Canton A, Hernandez C, Mesa J, Simo R . Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000; 23(1):80-3. DOI: 10.2337/diacare.23.1.80. View

Abu El-Asrar A, Missotten L, Geboes K . Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes. Clin Exp Ophthalmol. 2010; 38(1):57-64. DOI: 10.1111/j.1442-9071.2010.02194.x. View

Wei F, Tomizawa K . Functional loss of Cdkal1, a novel tRNA modification enzyme, causes the development of type 2 diabetes. Endocr J. 2011; 58(10):819-25. DOI: 10.1507/endocrj.ej11-0099. View

Looze C, Yui D, Leung L, Ingham M, Kaler M, Yao X . Proteomic profiling of human plasma exosomes identifies PPARgamma as an exosome-associated protein. Biochem Biophys Res Commun. 2008; 378(3):433-8. PMC: 2633355. DOI: 10.1016/j.bbrc.2008.11.050. View

Liebl J, Weitensteiner S, Vereb G, Takacs L, Furst R, Vollmar A . Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem. 2010; 285(46):35932-43. PMC: 2975216. DOI: 10.1074/jbc.M110.126177. View

Ahmadian M, Suh J, Hah N, Liddle C, Atkins A, Downes M . PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 19(5):557-66. PMC: 3870016. DOI: 10.1038/nm.3159. View

10.

Nentwich M, Ulbig M . Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes. 2015; 6(3):489-99. PMC: 4398904. DOI: 10.4239/wjd.v6.i3.489. View

11.

Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A . [TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]. Med Klin (Munich). 1995; 90(3):134-7. View

12.

Mohamed Q, Gillies M, Wong T . Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298(8):902-16. DOI: 10.1001/jama.298.8.902. View

13.

Shen L, Child A, Weber G, Folkman J, Aiello L . Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol. 2008; 126(6):793-9. DOI: 10.1001/archopht.126.6.793. View

14.

Huang H, Gandhi J, Zhong X, Wei Y, Gong J, Duh E . TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci. 2011; 52(3):1336-44. PMC: 3101693. DOI: 10.1167/iovs.10-5768. View

15.

Wei F, Nagashima K, Ohshima T, Saheki Y, Lu Y, Matsushita M . Cdk5-dependent regulation of glucose-stimulated insulin secretion. Nat Med. 2005; 11(10):1104-8. DOI: 10.1038/nm1299. View

16.

Higuchi A, Ohashi K, Shibata R, Sono-Romanelli S, Walsh K, Ouchi N . Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arterioscler Thromb Vasc Biol. 2009; 30(1):46-53. PMC: 3552615. DOI: 10.1161/ATVBAHA.109.198465. View

17.

Herzog J, Ehrlich S, Pfitzer L, Liebl J, Frohlich T, Arnold G . Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. Oncotarget. 2016; 7(19):27108-21. PMC: 5053636. DOI: 10.18632/oncotarget.8342. View

18.

Limb G, CHIGNELL A, Green W, Leroy F, Dumonde D . Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 1996; 80(2):168-73. PMC: 505411. DOI: 10.1136/bjo.80.2.168. View

19.

Ubeda M, Kemp D, Habener J . Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells. Endocrinology. 2004; 145(6):3023-31. DOI: 10.1210/en.2003-1522. View

20.

Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A . Peroxisome proliferator-activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis. 2009; 19(11):751-9. DOI: 10.1016/j.numecd.2009.04.011. View